Earnings release
Page 1
Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Global Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Sr. Manager-Investor Relations (203) 733-4987 david.trenk@haemonetics.com Haemonetics Reports Second Quarter and First Half Fiscal 2027 Results; Updates Fiscal 2027 Guidance Boston, MA, November 5, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial results for its second quarter of fiscal 2027, which ended September 26, 2026: 2nd Quarter 2027 Year-to-Date 2027 n Revenue, increase $358 million, 9% $697 million, 8% n Organic revenue increase 10.0% 8.0% n Earnings per diluted share $1.00 $1.72 n Adjusted earnings per diluted share $1.35 $2.49 n Cash flow from operating activities $128 million $180 million n Free cash flow $104 million $143 million __________ Excludes the impacts of currency fluctuation and the exit of certain liquid solution products. Chris Simon, Haemonetics’ CEO, stated: “Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities. With multiple catalysts for growth, we are focused on executing for our customers and translating our momentum into sustained success and shareholder value.” GAAP RESULTS Second quarter fiscal 2027 revenue was $357.8 million, up 9.3% compared with the second quarter of fiscal 2026. Business unit revenue and growth rates compared with the prior year period were as follows: Second Quarter Fiscal 2027 Reported (Dollars in Millions) Apheresis $204.8 12.6% MedSurg $153.0 5.1% Total net revenue $357.8 9.3% (1) (1) 1
Page 2
Gross margin was 61.7% in the second quarter of fiscal 2027, compared with 59.5% in the second quarter of fiscal 2026. The primary drivers of the increase in the gross margin percentage included tariffs refunded, the continued transformation of the product portfolio to higher-margin offerings and the absence of amortization of fair value inventory step-up. Operating expenses were $145.8 million, up $9.5 million, or 7.0%, compared with the second quarter of fiscal 2026. The increase in operating expenses was driven by higher personnel-related costs and freight charges. The Company had operating income of $75.1 million and a 21.0% operating margin in the second quarter of fiscal 2027, compared with operating income of $58.5 million and a 17.9% operating margin in the second quarter of fiscal 2026. The effective income tax rate was 26.3% in the second quarter of fiscal 2027, compared with 24.6% in the second quarter of fiscal 2026. The increase in the effective income tax rate was primarily due to valuation allowances recorded against deferred tax assets in jurisdictions with losses from recent acquisitions. Second quarter fiscal 2027 net income and earnings per diluted share were $46.3 million and $1.00, respectively, compared with $38.7 million and $0.81, respectively, in the second quarter of fiscal 2026. ADJUSTED RESULTS Second quarter organic revenue growth was 10.0% compared with the same period of fiscal 2026. Year-over-year organic revenue growth rates by business unit were as follows: Second Quarter Fiscal 2027 Organic Apheresis 13.6% MedSurg 5.5% Total net revenue 10.0% Second quarter fiscal 2027 adjusted gross margin was 61.9%, up 140 basis points compared with the prior year period. The primary drivers of the increase in the adjusted gross margin percentage included tariffs refunded and the continued transformation of the product portfolio to higher-margin offerings, partially offset by foreign currency fluctuations. Adjusted operating expenses were $127.6 million, up $16.8 million, or 15.2%, compared with the second quarter of fiscal 2026. The increase in adjusted operating expenses was driven by higher personnel-related costs and freight charges. Adjusted operating income for the second quarter of fiscal 2027 was $94.1 million, up $6.8 million, or 7.8%, compared with the second quarter of fiscal 2026. Adjusted operating margin was 26.3%, down 40 basis points when compared with the same period of fiscal 2026. The adjusted income tax rate for the second quarter of fiscal 2027 was 24.7%, which was flat when compared with 24.7% in the second quarter of fiscal 2026. Second quarter fiscal 2027 adjusted net income was $62.6 million, up $2.3 million, or 3.8%, and adjusted earnings per diluted share was $1.35, up 6.3%, each when compared with the same period of fiscal 2026. BALANCE SHEET AND CASH FLOW Cash on hand as of September 26, 2026 was $260.7 million, an increase of $15.3 million since the end of fiscal 2026, primarily driven by cash flow provided from operating activities, partially offset by cash outflows for the repayment of revolving credit facility borrowings, capital expenditures and contingent consideration payments. 2
Page 3
Second quarter fiscal 2027 cash flow from operating activities was $128.1 million, up $16.8 million, and free cash flow was $103.8 million, up $15.1 million, each when compared with the same period of fiscal 2026. The primary driver of increased operating cash flow as compared to the same period of fiscal 2026 was favorable working capital adjustments driven by the timing of payments made and cash collections. Free cash flow was impacted by higher capital expenditures, which was partially offset by lower non-cash transfers from Haemonetics equipment. FISCAL 2027 GUIDANCE The Company updated its previous fiscal 2027 guidance as follows: Total Company Previous Guidance Current Guidance Reported Revenue 5 - 8% 8 - 11% 53rd week impact (~2%) (~2%) Strategic exits ~1% ~1% Currency impact 0 - 1% 0 - 1% Organic Revenue 4 - 7% 6 - 9% Adjusted operating margin 50 – 100 bps expansion YoY 0 – 50 bps expansion YoY Adjusted earnings per diluted share Comparable to reported revenuegrowth Comparable to reported revenuegrowth Free cash flow conversion ~80% >80% __________ Includes the impact of the exit of certain liquid solution products. Previous guidance includes approximately low- to mid-single-digit growth in Apheresis and mid-single digit growth in MedSurg. Current guidance includes high- single-digit growth in Apheresis and mid-single digit growth in MedSurg. Organic growth guidance also includes nominal historical pre-acquisition revenue of Vivasure to provide a comparable view of period-over-period performance. Free cash flow conversion is calculated as free cash flow divided by adjusted net income. WEBCAST CONFERENCE CALL AND RESULTS ANALYSIS The Company will host a conference call with investors and analysts to discuss second quarter fiscal 2027 results on Thursday, November 5, 2026 at 8:00 a.m. ET. The call can be accessed via teleconference at https://register- conf.media-server.com/register/BIf24df80f681345eb86967db309c34804. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start. Alternatively, a live webcast of the call can be accessed on Haemonetics’ investor relations website at the following direct link: https://edge.media-server.com/mmc/p/kf8g7up6. The Company has also provided a supplemental earnings presentation for its second quarter of fiscal 2027, which is available on its website and can be found at the following direct link: https://haemonetics.gcs-web.com/static- files/96c2477d-9271-40e4-93f2-f3691621b414. (1) (2) (3) (1) (2) (3) 3
Page 4
ABOUT HAEMONETICS Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor- guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com. FORWARD-LOOKING STATEMENTS Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the Company’s strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company’s market and regional alignment initiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company’s share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, availability and demand for the Company’s products; the Company’s ability to successfully develop and market new products and technologies; the impact of competitive products and pricing; product quality; disruptions caused by cybersecurity events; any failure to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures; pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation; manufacturing, distribution and supply chain disruptions and cost increases; the Company’s ability to implement as planned and realize estimated cost savings from the market and regional alignment initiative; the effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures; regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions; indebtedness incurred by the Company, including the conditional conversion feature of its convertible notes; the Company’s ability to protect its intellectual property; litigation; and the impact of share repurchases on the Company’s stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program’s effectiveness. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements. 4
Page 5
MANAGEMENT’S USE OF NON-GAAP MEASURES This press release contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in the Company’s underlying businesses. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure. When used in this release, organic revenue growth excludes the impact of currency fluctuation and the exit of certain liquid solution products. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted interest and other income/expense, adjusted provision for income taxes, adjusted net income and adjusted earnings per diluted share exclude restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, amortization of fair value inventory step-up, acquisition and integration related costs, certain tax settlements, unusual or infrequent and material litigation-related charges, equity method losses, impairment of intangible assets and remeasurement of contingent consideration. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. The adjustments to provision for income taxes are calculated based on the jurisdictions in which pre-tax adjustments occurred. Free cash flow is defined as cash provided by operating activities less capital expenditures and additions to Haemonetics equipment, net of the proceeds from the sale of property, plant and equipment. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies. A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included at the end of the financial sections of this press release as well as on the Company’s website at www.haemonetics.com. The Company does not attempt to provide reconciliations of forward-looking adjusted operating margin guidance, adjusted earnings per diluted share guidance or free cash flow conversion guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs, impairment charges and capital expenditures, is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company’s financial performance. 5
Page 6
Haemonetics Corporation Financial Summary Condensed Consolidated Statements of Income (Unaudited) Three Months Ended Six Months Ended 9/26/2026 9/27/2025 Inc/(Dec) % 9/26/2026 9/27/2025 Inc/(Dec) % (Dollars and Shares in Thousands, ExceptPer Share Data) (Dollars and Shares in Thousands, ExceptPer Share Data) Net revenues $ 357,759 $ 327,315 9.3% $ 697,139 $ 648,709 7.5% Cost of goods sold 136,846 132,571 3.2% 273,423 261,721 4.5% Gross profit 220,913 194,744 13.4% 423,716 386,988 9.5% Research and development 17,029 14,872 14.5% 33,229 31,133 6.7% Selling, general andadministrative 118,361 101,615 16.5% 237,302 212,334 11.8% Amortization of acquiredintangible assets 10,403 11,182 (7.0)% 20,607 22,574 (8.7)% Impairment of intangible assets — 8,584 (100.0)% — 8,584 (100.0)% Total Operating expenses 145,793 136,253 7.0% 291,138 274,625 6.0% Operating income 75,120 58,491 28.4% 132,578 112,363 18.0% Interest and other expense, net (12,261) (7,206) 70.1% (22,145) (15,909) 39.2% Income before provision for incometaxes 62,859 51,285 22.6% 110,433 96,454 14.5% Provision for income taxes 16,554 12,601 31.4% 31,118 23,739 31.1% Net income $ 46,305 $ 38,684 19.7% $ 79,315 $ 72,715 9.1% Net income per common shareassuming dilution $ 1.00 $ 0.81 23.5% $ 1.72 $ 1.51 13.9% Weighted average sharesoutstanding Basic 45,500 47,590 45,430 47,850 Diluted 46,463 47,664 46,084 48,009 Profit Margins: Inc/(Dec) % Inc/(Dec) % Gross profit 61.7 % 59.5 % 2.2% 60.8 % 59.7 % 1.1% Research and development 4.8 % 4.5 % 0.3% 4.8 % 4.8 % —% Selling, general and administrative 33.1 % 31.0 % 2.1% 34.0 % 32.7 % 1.3% Operating income 21.0 % 17.9 % 3.1% 19.0 % 17.3 % 1.7% Income before provision for incometaxes 17.6 % 15.7 % 1.9% 15.8 % 14.9 % 0.9% Net income 12.9 % 11.8 % 1.1% 11.4 % 11.2 % 0.2% 6
Page 7
Revenue Analysis by Business Unit (Unaudited) Three Months Ended 9/26/2026 9/27/2025 Reportedgrowth Currencyimpact Strategic Exits Organicgrowth (Dollars in Thousands) Revenues by business unit Plasma $ 162,584 $ 139,614 16.5 % (0.6)% (0.6)% 17.7 % Other 42,221 42,204 — % (0.2)% — % 0.2 % Apheresis $ 204,805 $ 181,818 12.6 % (0.6)% (0.4)% 13.6 % Interventional Technologies $ 60,508 $ 59,073 2.4 % (0.8)% — % 3.2 % Blood Management Technologies 92,446 86,424 7.0 % — % — % 7.0 % MedSurg $ 152,954 $ 145,497 5.1 % (0.4)% — % 5.5 % Total net revenues $ 357,759 $ 327,315 9.3 % (0.4)% (0.3)% 10.0 % Six Months Ended 9/26/2026 9/27/2025 Reportedgrowth Currencyimpact Strategic Exits Organicgrowth (Dollars in Thousands) Revenues by business unit Plasma $ 318,108 $ 284,688 11.7 % (0.3)% (0.9)% 12.9 % Other 78,015 78,866 (1.1)% 0.1 % — % (1.2)% Apheresis $ 396,123 $ 363,554 9.0 % (0.1)% (0.7)% 9.8 % Interventional Technologies $ 120,450 $ 117,556 2.5 % (0.5)% — % 3.0 % Blood Management Technologies 180,566 167,599 7.7 % 0.2 % — % 7.5 % MedSurg $ 301,016 $ 285,155 5.6 % (0.1)% — % 5.7 % Total net revenues $ 697,139 $ 648,709 7.5 % (0.1)% (0.4)% 8.0 % __________ Includes the impact of the exit of certain liquid solution products. Includes nominal historical pre-acquisition revenue of Vivasure. Other includes blood collection and processing devices and disposables. Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the MedSurg business unit. Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit. (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) 7
Page 8
Condensed Consolidated Balance Sheets (Unaudited) September 26, 2026 March 28, 2026 (Dollars in Thousands) Assets Cash and cash equivalents $ 260,712 $ 245,440 Accounts receivable, net 224,952 216,855 Inventories, net 305,006 306,370 Other current assets 64,857 66,214 Total current assets 855,527 834,879 Property, plant & equipment, net 307,921 305,761 Intangible assets, net 426,364 447,655 Goodwill 657,104 656,368 Other assets 163,689 151,262 Total assets $ 2,410,605 $ 2,395,925 Liabilities & Stockholders' Equity Short-term debt & current maturities $ 9,643 $ 5,015 Other current liabilities 291,195 277,584 Total current liabilities 300,838 282,599 Long-term debt 1,114,118 1,219,565 Other long-term liabilities 97,152 97,441 Stockholders' equity 898,497 796,320 Total liabilities & stockholders' equity $ 2,410,605 $ 2,395,925 8
Page 9
Condensed Consolidated Statements of Cash Flows (Unaudited) Six Months Ended September 26, 2026 September 27, 2025 (Dollars in Thousands) Cash Flows from Operating Activities: Net income $ 79,315 $ 72,715 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 54,871 57,013 Amortization of fair value inventory step-up — 4,491 Share-based compensation expense 19,539 16,901 Impairment of intangible assets — 8,584 Deferred income taxes 3,234 (3,956) Change in other non-cash operating activities 5,389 2,361 Change in operating assets and liabilities: Change in accounts receivable, net (8,064) (3,702) Change in inventories, net 978 25,058 Change in prepaid income taxes 2,428 3,136 Change in other assets and other liabilities (18,277) (23,688) Change in accounts payable and accrued expenses 41,010 (30,197) Net cash provided by operating activities 180,423 128,716 Cash Flows from Investing Activities: Capital expenditures (22,677) (8,770) Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment (15,657) (29,149) Proceeds from sale of property, plant and equipment 813 417 Other investments (9,000) (25,966) Net cash used in investing activities (46,521) (63,468) Cash Flows from Financing Activities: Repayments, net of borrowings (103,125) (3,125) Share repurchases — (75,000) Contingent consideration payments (17,597) — Proceeds from employee stock programs 5,500 4,001 Cash used to net share settle employee equity awards (3,888) (4,795) Other financing activities (29) (75) Net cash used in financing activities (119,139) (78,994) Effect of exchange rates on cash and cash equivalents 509 3,409 Net Change in Cash and Cash Equivalents 15,272 (10,337) Cash and Cash Equivalents at Beginning of the Period 245,440 306,763 Cash and Cash Equivalents at End of Period $ 260,712 $ 296,426 Free Cash Flow Reconciliation: Cash provided by operating activities $ 180,423 $ 128,716 Capital expenditures (22,677) (8,770) Additions to Haemonetics equipment (15,657) (29,149) Proceeds from sale of property, plant and equipment 813 417 Free cash flow $ 142,902 $ 91,214 9
Page 10
Reconciliation of Adjusted Measures for Second Quarter of FY27 and FY26 (Unaudited) Gross profit Operatingexpenses Operatingincome Interest andother(expense)income Provision(benefit) forincome taxes Net income(loss) Earnings perdiluted share Three Months Ended September 26,2026: (Dollars in Thousands, Except Per Share Data) Reported $ 220,913 $ 145,793 $ 75,120 $ (12,261) $ 16,554 $ 46,305 $ 1.00 Amortization of acquired intangibleassets — (10,403) 10,403 — 2,160 8,243 0.18 Integration and transaction costs 924 (1,627) 2,551 (2) 91 2,458 0.05 Restructuring costs (219) 7 (226) — (35) (191) — Restructuring related costs 11 — 11 — — 11 — Digital transformation costs — (5,405) 5,405 — 1,305 4,100 0.09 Litigation-related charges — (44) 44 — — 44 — Remeasurement of contingentconsideration — (748) 748 — 161 587 0.01 Equity method losses — — — 1,354 333 1,021 0.02 Discrete tax items — — — — 1 (1) — Adjusted $ 221,629 $ 127,573 $ 94,056 $ (10,909) $ 20,570 $ 62,577 $ 1.35 Adjusted, as a percentage of netrevenues 61.9 % 35.7 % 26.3 % 17.5 % Gross profit Operatingexpenses Operatingincome (loss) Interest andother expense Provision(benefit) forincome taxes Net income(loss) Earnings perdiluted share Three Months Ended September 27,2025: (Dollars in Thousands, Except Per Share Data) Reported $ 194,744 $ 136,253 $ 58,491 $ (7,206) $ 12,601 $ 38,684 $ 0.81 Amortization of acquired intangibleassets — (11,182) 11,182 — 2,810 8,372 0.19 Amortization of fair value inventorystep-up 2,055 — 2,055 — 505 1,550 0.03 Integration and transaction costs 1,336 (183) 1,520 — 387 1,133 0.02 Restructuring costs (142) (346) 204 — 75 129 — Restructuring related costs 38 (16) 54 — 12 42 — Digital transformation costs — (5,054) 5,054 — 1,236 3,818 0.08 Litigation-related charges — (220) 220 — 53 167 — Impairment of intangible assets — (8,584) 8,584 — 2,147 6,437 0.14 Remeasurement of contingentconsideration — 87 (87) — (57) (30) — Adjusted $ 198,031 $ 110,755 $ 87,277 $ (7,206) $ 19,769 $ 60,302 $ 1.27 Adjusted, as a percentage of netrevenues 60.5 % 33.8 % 26.7 % 18.4 % 10
Page 11
Reconciliation of Adjusted Measures for Year-to-Date of FY27 and FY26 (Unaudited) Gross profit Operatingexpenses Operatingincome (loss) Interest andother(expense)income Provision(benefit) forincome taxes Net income(loss) Earnings perdiluted share Six Months Ended September 26, 2026: (Dollars in Thousands, Except Per Share Data) Reported $ 423,716 $ 291,138 $ 132,578 $ (22,145) $ 31,118 $ 79,315 $ 1.72 Amortization of acquired intangibleassets — (20,607) 20,607 — 4,445 16,162 0.35 Integration and transaction costs 2,209 (3,108) 5,317 (2) (326) 5,641 0.12 Restructuring costs 564 (1,508) 2,072 — 502 1,570 0.03 Restructuring related costs 21 50 (29) — — (29) — Digital transformation costs — (11,568) 11,568 — 2,868 8,700 0.19 Litigation-related charges — (501) 501 — — 501 0.01 Remeasurement of contingentconsideration — (701) 701 — 156 545 0.01 Equity method losses — — — 2,354 588 1,766 0.04 Discrete tax items — — — — (695) 695 0.02 Adjusted $ 426,510 $ 253,195 $ 173,315 $ (19,793) $ 38,656 $ 114,866 $ 2.49 Adjusted, as a percentage of netrevenues 61.2 % 36.3 % 24.9 % 16.5 % Gross profit Operatingexpenses Operatingincome (loss) Interest andother(expense)income Provision(benefit) forincome taxes Net income(loss) Earnings perdiluted share Six Months Ended September 27, 2025: (Dollars in Thousands, Except Per Share Data) Reported $ 386,988 $ 274,625 $ 112,363 $ (15,909) $ 23,739 $ 72,715 $ 1.51 Amortization of acquired intangibleassets — (22,574) 22,574 — 5,733 16,841 0.36 Amortization of fair value inventorystep-up 4,491 — 4,491 — 1,123 3,368 0.07 Integration and transaction costs 2,366 (1,836) 4,202 2,022 1,599 4,625 0.10 Restructuring costs (526) (1,997) 1,470 — 365 1,105 0.02 Restructuring related costs 24 (87) 112 — 21 91 — Digital transformation costs — (10,409) 10,409 — 2,570 7,839 0.16 Litigation-related charges — (804) 804 — 201 603 0.01 Impairment of intangible assets — (8,584) 8,584 — 2,147 6,437 0.13 Remeasurement of contingentconsideration — 180 (180) — (91) (89) — Adjusted $ 393,343 $ 228,514 $ 164,829 $ (13,887) $ 37,407 $ 113,535 $ 2.36 Adjusted, as a percentage of netrevenues 60.6 % 35.2 % 25.4 % 17.5 % 11